Assessing the achievability of optimal therapy in patients with heart failure with reduced ejection fraction; a difficult task?

20 May 2023 (09:00 - 09:45)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Miss Florence Bernier

Quebec Heart and Lung Institute, Quebec (Canada)

6 More presentations in this session

Presentation thumbnail

Pharmacologic transition in the care of patients with heart failure with reduced ejection fraction - a real life analysis

Doctor I. Cruz (Penafiel, PT)

Abstract Slides

Presentation thumbnail

Risk of safety events considered potential barriers to utilization of guideline-directed medical therapy among patients with worsening heart failure and ejection fraction 30% or lower

Doctor S. Greene (Durham, US)

Abstract Slides

Presentation thumbnail

Clinical outcomes in patients with ischemic versus non-ischemic cardiomyopathy after angiotensin-neprilysin inhibition therapy

Doctor C. Sabanoglu (Ankara, TR)

Abstract Slides

Presentation thumbnail

Five-year retrospective analysis of treatment efficacy effectiveness of sacubitril/valsartan in heart failure with reduced ejection fraction with end-stage renal disease

Doctor B. Hsiao (Taipei, TW)

Abstract Slides

Presentation thumbnail

Is downtitration of diuretic therapy safe in patients with heart failure?

Mr C. Geraeds (Maastricht, NL)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure - pharmacotherapy 1

The Event

Event poster

Heart Failure 2023

20 May 2023 09:00 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Webinar

MRAs in heart failure: what's old is new again

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources